Glenmark Pharma gains after American subsidiary launches Olopatadine generic
Glenmark Pharmaceuticals added 1.53% to Rs 1588.65 after the company's subsidiary Glenmark Therapeutics Inc., USA, announced the launch of OTC product Olopatadine Hydrochloride Ophthalmic Solution.
| Ticker |
Sentiment |
Impact |
|
ALC
|
Neutral
|
15 %
|
|
NVS
|
Neutral
|
15 %
|
